Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lorlatinib”

64 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 64 results

Not applicableStudy completedNCT03727477
What this trial is testing

Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib

Who this might be right for
Non-small Cell Lung Cancer MetastaticALK Gene Rearrangement PositiveROS-1 Gene Rearrangement Positive
Intergroupe Francophone de Cancerologie Thoracique 291
Post-approval studies (Phase 4)Study completedNCT04541706
What this trial is testing

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Pfizer 100
Not applicableNot Yet RecruitingNCT07823725
What this trial is testing

TailorDose Lung: Decentralized TDM of Taxanes and ALK Inhibitors Using Capillary Self-Sampling

Who this might be right for
Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)
Karolinska Institutet 40
Not applicableLooking for participantsNCT07374614
What this trial is testing

Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

Who this might be right for
Non-Small Cell Lung CancerALKIruplinalkib+3 more
Peking University Shenzhen Hospital 20
Large-scale testing (Phase 3)Looking for participantsNCT03126916
What this trial is testing

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Who this might be right for
GanglioneuroblastomaGanglioneuroblastoma, NodularNeuroblastoma
Children's Oncology Group 750
Not applicableLooking for participantsNCT07633626
What this trial is testing

Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib

Who this might be right for
Advanced ALK/ROS1-positive NSCLCCarcinoma, Non-Small-Cell Lung (NSCLC)Lung Adenocarcinoma+3 more
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo 24
Not applicableNot Yet RecruitingNCT06652555
What this trial is testing

The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study

Who this might be right for
ALKNSCLC
Shanghai Pulmonary Hospital, Shanghai, China 100
Large-scale testing (Phase 3)Not Yet RecruitingNCT06858410
What this trial is testing

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

Who this might be right for
Neoadjuvant Non-Small Cell Lung Cancer
Guangdong Association of Clinical Trials 36
Post-approval studies (Phase 4)Not Yet RecruitingNCT06893354
What this trial is testing

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

Who this might be right for
NSCLC
The First Affiliated Hospital of Guangzhou Medical University 20
Early research (Phase 1)Study completedNCT03542305
What this trial is testing

Lorlatinib Renal Impairment Study

Who this might be right for
Renal Impairment
Pfizer 29
Testing effectiveness (Phase 2)Active Not RecruitingNCT05297890
What this trial is testing

Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Who this might be right for
Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
CStone Pharmaceuticals 70
Not applicableNot Yet RecruitingNCT07674524
What this trial is testing

Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)HyperlipidemiaALK Gene Mutation+1 more
Sun Yat-sen University 160
Not applicableStudy completedNCT06678555
What this trial is testing

Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 22
Testing effectiveness (Phase 2)Ended earlyNCT02584634
What this trial is testing

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer 43
Not applicableStudy completedNCT06282991
What this trial is testing

Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

Who this might be right for
Non-Small Cell Lung Carcinoma
Pfizer 73
Testing effectiveness (Phase 2)Active Not RecruitingNCT05740943
What this trial is testing

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Who this might be right for
Stage III NSCLCSurgery
Guangdong Provincial People's Hospital 48
Not applicableEnded earlyNCT04753658
What this trial is testing

Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

Who this might be right for
Neuroblastoma
Pfizer 15
Testing effectiveness (Phase 2)Looking for participantsNCT06092086
What this trial is testing

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Who this might be right for
ALK Positive Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 126
Early research (Phase 1)Ended earlyNCT03726333
What this trial is testing

Hepatic Impairment Study for Lorlatinib in Cancer Patients

Who this might be right for
Advanced Cancers
Pfizer 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT04621188
What this trial is testing

Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

Who this might be right for
Non Small Cell Lung Cancer Metastatic
Intergroupe Francophone de Cancerologie Thoracique 54
Next Page